Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

15 Jun 2007

Abstract excerpt

Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we detail the pharmacologic properties of a prototype of a new series of inhibitors of class I PI3K. PI103 is a potent inhibitor with low IC50 values against recombinant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17575152
DOI: 10.1158/0008-5472.can-06-4615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-KinasesPMID 17575152Read ↗

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the ClinicSemantic proximity Read ↗

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.Semantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read ↗

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapySemantic proximity Read ↗

Activity of any class IA PI3K isoform can sustain cell proliferation and survival.Semantic proximity Read ↗

The emerging role of PI3K inhibitors for solid tumour treatment and beyond.Semantic proximity Read ↗

Advances in subunits of PI3K class I in cancer.Semantic proximity Read ↗

PI3K inhibitors for cancer treatment: where do we stand?Semantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Challenges in the clinical development of PI3K inhibitors.Semantic proximity Read ↗

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.